Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ningbo Liu

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Radiation Oncology (London, England)|July 4, 2023
Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancerJianfeng Peng, Lemeng Zhang, Liping Wang, et al.
Frontiers in Oncology|June 2, 2022
Practice Patterns of Treatment Strategy of Limited-Stage Small-Cell Lung Cancer: Survey of Chinese OncologistsChang Xu, Meng Li, Xuwei Cai, et al.
Annals of Translational Medicine|November 26, 2020
Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinomaXi Chen, Hui Wei, Dong Qian, et al.
Journal of Cancer Research and Clinical Oncology|December 2, 2019
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trialsJing Luo, Xinchi Dai, Hua Hu, et al.
Molecular Cancer Therapeutics|February 28, 2013
ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALKYunguang Sun, Kamila A Nowak, Nicholas G Zaorsky, et al.
Carcinogenesis|May 15, 2013
PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186Hongli Li, Chonggao Yin, Baogang Zhang, et al.
Annals of Translational Medicine|November 26, 2020
Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapyJie Dong, Wencheng Zhang, Tian Zhang, et al.
Annals of Translational Medicine|November 26, 2020
Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patientsDong Han, Jiajia Zhang, Jingjing Zhao, et al.
Annals of Translational Medicine|November 26, 2020
Annual report of the esophageal cancer radiation group of the Department of Radiotherapy, Tianjin Medical University Cancer Institute & HospitalQingsong Pang, Xiaoying Wei, Wencheng Zhang, et al.
Annals of Translational Medicine|November 26, 2020
The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinomaJingjing Zhao, Tongda Lei, Tian Zhang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Radiation Oncology (London, England)|July 4, 2023
Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancerJianfeng Peng, Lemeng Zhang, Liping Wang, et al.
Frontiers in Oncology|June 2, 2022
Practice Patterns of Treatment Strategy of Limited-Stage Small-Cell Lung Cancer: Survey of Chinese OncologistsChang Xu, Meng Li, Xuwei Cai, et al.
Annals of Translational Medicine|November 26, 2020
Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinomaXi Chen, Hui Wei, Dong Qian, et al.
Journal of Cancer Research and Clinical Oncology|December 2, 2019
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trialsJing Luo, Xinchi Dai, Hua Hu, et al.
Molecular Cancer Therapeutics|February 28, 2013
ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALKYunguang Sun, Kamila A Nowak, Nicholas G Zaorsky, et al.
Carcinogenesis|May 15, 2013
PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186Hongli Li, Chonggao Yin, Baogang Zhang, et al.
Annals of Translational Medicine|November 26, 2020
Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapyJie Dong, Wencheng Zhang, Tian Zhang, et al.
Annals of Translational Medicine|November 26, 2020
Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patientsDong Han, Jiajia Zhang, Jingjing Zhao, et al.
Annals of Translational Medicine|November 26, 2020
Annual report of the esophageal cancer radiation group of the Department of Radiotherapy, Tianjin Medical University Cancer Institute & HospitalQingsong Pang, Xiaoying Wei, Wencheng Zhang, et al.
Annals of Translational Medicine|November 26, 2020
The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinomaJingjing Zhao, Tongda Lei, Tian Zhang, et al.
Pageof 6